Emerald Advisers’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Emerald Advisers’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-495,638	Closed	-$18.5M	–	303
2021 Q2	$18.5M	Sell	495,638 -29,294	-6%	-$898K	0.67%	66
2021 Q1	$13.4M	Sell	524,932 -59,410	-10%	-$1.52M	0.48%	88
2020 Q4	$12.9M	Buy	584,342 +66,858	+13%	+$1.47M	0.43%	94
2020 Q3	$9.31M	Sell	517,484 -3,303	-0.6%	-$68.4K	0.38%	88
2020 Q2	$13.2M	Sell	520,787 -147,337	-22%	-$3.17M	0.58%	68
2020 Q1	$12.3M	Sell	668,124 -33,217	-5%	-$646K	0.71%	54
2019 Q4	$15.5M	Sell	701,341 -172,268	-20%	-$3.47M	0.65%	61
2019 Q3	$12.5M	Sell	873,609 -113,048	-11%	-$1.62M	0.59%	72
2019 Q2	$15.5M	Sell	986,657 -9,703	-1%	-$132K	0.62%	68
2019 Q1	$14.6M	Sell	996,360 -13,970	-1%	-$161K	0.59%	64
2018 Q4	$10.8M	Buy	1,010,330 +37,708	+4%	+$496K	0.53%	76
2018 Q3	$14.8M	Buy	972,622 +369,114	+61%	+$5.37M	0.55%	84
2018 Q2	$7.39M	Buy	603,508 +574,804	+2,003%	+$7.22M	0.28%	111
2018 Q1	$274K	Sell	28,704 -800	-3%	-$8.63K	0.01%	231
2017 Q4	$266K	Buy	+29,504	New	+$217K	0.01%	224
2015 Q2	–	Sell	-69,945	Closed	-$1.55M	–	387
2015 Q1	$1.55M	Buy	+69,945	New	+$1.57M	0.08%	225

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Emerald Advisers's DRNA Position: Q3 2021 in Review

Emerald Advisers sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 495,638 shares — an estimated $18.5M sold.

Emerald Advisers first reported a position in DRNA in Q1 2015 and held it in 16 quarters. The position peaked at $18.5M in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Emerald Advisers reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Emerald Advisers sold 495,638 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $18.5M.
Emerald Advisers first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2015 and held it in 16 quarters.
Emerald Advisers's Dicerna Pharmaceuticals, Inc. position peaked at $18.5M in Q2 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Emerald Advisers's 13F filing for Q3 2021, filed 28 Oct 2021.